SUMMARY -Th e aim of this study was to investigate the role of the QuantiFERON-TB Gold In-Tube test (QFT-GIT) in detecting latent tuberculosis in immunocompromised patients before introducing tumor necrosis factor (TNF-α) antagonists. Th e study included 300 subjects of similar age. Th e study group comprised of 150 QuantiFERON (QFT) positive subjects with rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, while control group comprised of 150 QFT negative respondents with the same diseases. Exhaustive medical history was documented for all patients. Screening tests were performed including QFT-GIT, tuberculin skin test (TST), chest radiography and detection of Mycobacterium tuberculosis in sputum culture 2 times. A positive QFT-GIT test result, regardless of TST result, was considered as an indication for latent tuberculosis infection (LTBI) treatment. Results of this study showed good correlation between the conclusive results of QFT-GIT and TST. All study group patients had normal clinical fi ndings, normal radiologic fi ndings and negative results of sputum microbiological analysis during the course of prophylaxis and after its completion and during the course of biological therapy. Conversion of positive QFT-GIT test to negative was observed in 4% of study group patients, while QFT negative respondents remained negative. Th ere was a statistically signifi cant positive correlation between QFT-GIT, TST results and patient age, smoking habit and contact with tuberculosis. Study results showed that along with good clinical evaluation and detailed medical history, it is important to conduct testing in order to avoid disease progression or unnecessary isoniazid prophylaxis.
Introduction
Since tuberculosis is associated with tumor necrosis factor alpha (TNF-α) blockade, the widespread use of TNF-α antagonists for infl ammatory diseases has led to an increased rate of active tuberculosis cases 1 . Arthritis patients are at a higher risk of infection because of the disease and immunosuppressive therapies, including prednisolone, disease-modifying anti-rheumatic drugs (DMARDs) and TNF-α antagonists 2, 3 . Most biologics appear to be similar in their propensity to promote serious infection 4 . Latent tuberculosis infection (LTBI) is the presence of Mycobacterium tuberculosis (TB) without any symptoms of active disease. Detection of LTBI is important in clinical practice due to its associated risk of progression to active disease, especially in immunocompromised population 1 . Th ere are no clinical symptoms and signs in LTBI and no gold standard laboratory test is available. Until recently, the tuberculin skin test (TST) was the only test available for diagnosing LTBI. Th e sensitivity and specifi city of TST are considered generally low, under 100%, with the occurrence of false-negative results due to depressed immunity and false-positive results due to previous Bacillus Calmette-Guérin (BCG) immunization and cross-reactivity with opportunistic mycobacteria. It also has limitations including a signifi cant false-positive rate and poor sensitivity in immunocompromised individuals 2, 5, 6 . Another available test for detection of LTBI is QuantiFERON-TB Gold InTube (QFT-GIT) test, which has been demonstrated to have comparable sensitivity to TST for LTBI, but its strength appears to be in its superior specifi city, particularly in BCG-vaccinated population and its better correlation with the known TB risk factors.
It seems to off er better possibility of improved detection of LTBI, however, data on its performance in arthritis patents are limited [5] [6] [7] [8] [9] [10] [11] [12] [13] . Th is article reviews the role of the QFT-GIT test in the diagnosis of latent tuberculosis infection in arthritis patients prior and during TNF-α antagonist therapy.
Patients and Methods
During one-year study period, 300 patients underwent treatment with TNF-α antagonists. Th e study group comprised of 150 QuantiFERON (QFT) positive patients (mean age, 51.8; 82 women and 68 men) suff ering from rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, while control group comprised of 150 QFT negative respondents (mean age, 45.98; 75 women and 75 men) with the same diseases. Exhaustive medical history was documented for all subjects. A pre-structured questionnaire on comorbidity, drug intake, family history of tuberculosis, epidemiological history (tuberculosis contact, country of birth), occupation, BCG immunization, smoking habits and alcohol consumption was fi lled out for each subject.
During the fi rst clinical examination, both QFT-GIT (QFT-GIT test; Cellestis Ltd., Carnegie, Victoria, Australia) and TST were performed. Th e QFT-GIT test was performed according to the manufacturer's instructions and positive test result was defi ned as ≥0.35 IU/mL, while the TST was performed using the Mantoux method with 2 tuberculin units (TU) of purifi ed protein derivative RT23 (Statens Serum Institute, Copenhagen, Denmark) on the volar side of the forearm. Induration size was measured after 48-72 hours, while 10-mm induration was positive cut-off value for the TST.
To rule out active disease in all subjects, detailed clinical evaluation included physical examination, chest radiographs and microbiological analysis for Mycobacterium tuberculosis (sputum culture 2 times).
In subjects with positive QFT-GIT test regardless of TST result and normal chest radiographs and negative microbiological examination, 6-month prophylaxis with isoniazid was introduced, whereas TNF-α antagonist treatment was initiated 6 weeks after isoniazid introduction. In QFT negative subjects, TNF-α antagonist treatment was introduced immediately. TST was administered 3 days prior to QFT-GIT to rule out inaccurate results, since TST appeared to affect QFT-GIT responses, especially in QFT-GIT negative subjects but only after 3 days and may apparently persist for several months, although with scarce evidence 14 . In all subjects, second clinical evaluation was performed six months after the fi rst visit and included physical examination and chest radiographs, while third clinical evaluation was performed after one year and included physical examination, chest radiographs, microbiological analysis for Mycobacterium tuberculosis (sputum culture 2 times) and QFT-GIT test.
Ethics
Prior to signing a written consent, each patient was thoroughly informed about the purpose of the study. Th e study was approved by the Ethics Committee, School of Medicine, University of Zagreb.
Statistics
Statistical analysis was performed using the STA-TISTICA 12.0 software package (StatSoft, Inc., USA). Basic statistical parameters for continuous vari-ables and frequency tables for categorical variables were calculated separately for both control and study groups. Th e c 2 -test was used to identify percentage difference between the groups. Mann-Whitney U test was used to assess the possible statistically signifi cant diff erences between the two groups, whereas KruskalWallis ANOVA was employed for more than two groups. Linear regression analysis was used to determine the possible correlation between QFT-GIT and TST results.
To defi ne the infl uence of selected predictor variables (age, sex, immune diseases, other diseases, smoking, alcohol consumption, and contact with tuberculosis) on the dependent variable (QFT-GIT, TST), multiple regression analysis and general regression model (GRM) were used. Pareto distribution diagram was used to show GRM results in T value. Statistical signifi cance at 0.05 level was used in all methods.
Results
Th e incidence of immune system diseases was equally distributed in subjects with positive QFT-GIT and TST. Rheumatoid arthritis was the most prevalent disease in both QFT and TST positive subjects (38.67% QFT positive and 40% TST positive), followed by Crohn's disease (24% QFT positive and 23.33% TST positive), whereas other diseases were less frequent. Adalimumab was the most prescribed biological therapy (Table 1) .
Among QFT positive subjects, 80.67% were also TST positive (Table 2) , whereas 2.67% of QFT negative respondents had positive TST results. Linear regression analysis revealed a very good correlation between QFT-GIT and TST results (R=0.74; p= 0.000000).
Th irty percent of study subjects and 10% of control subjects had a history of tuberculosis contact. Th e percentage of patients with tuberculosis contact was signifi cantly lower in the control group (χ 2 =14.2; p= 0.0002).
Tuberculosis contact as a risk factor had a statistically signifi cant eff ect on QFT-GIT and TST results. Seventy-fi ve percent of respondents with a history of tuberculosis contact had positive QFT-GIT test results, while 80% had positive TST results. In the QFT positive group, 25 of 45 subjects with a history of tuberculosis contact had moderate reaction (fi rm bump (Table 3) showed that the variables of age, smoking and tuberculosis contact had a statistically signifi cant impact on the QFT-GIT and TST results. Regression analysis confi rmed a statistically signifi cant correlation between the selected predictor variables and QFT-GIT test results (R=0.55; p= 0.000002). Beta coeffi cient values indicated the variables of tuberculosis contact (β=0.23; p=0.000152), subject age (β=0.21; p=0.001415) and smoking habit (β=0.11; p=0.048893) to have by far greatest statistically signifi cant eff ect on QFT-GIT test results.
A statistically signifi cant correlation was also confi rmed between the same predictor variables and TST results (R=0.71; p=0.000000). Tuberculosis contact (β=0.47; p=0.000000), subject age (β=0.15; p=0.016634) and smoking habits had the greatest, statistically signifi cant contribution to the overall correlation.
After one-year study period, 4% of subjects from the study group experienced conversion of QFT-GIT test from positive to negative, whereas all QFT negative subjects remained negative. According to the regression model results, none of the selected predictor variables had a statistically signifi cant impact on QFT-GIT test negativization after chemoprophylaxis.
After six-month and one-year period, all subjects had normal clinical, radiological and microbiological fi ndings of sputum, regardless of chemoprophylaxis and biological therapy.
Discussion
It is important to establish accurate diagnosis of latent tuberculosis in patients suff ering from infl ammatory autoimmune diseases during TNF-α antagonist therapy due to the high risk of its progression to an active form and an increased risk of developing some of the more complicated forms of tuberculosis 1, 3, 5 . Based on the QFT-GIT test results, subjects in this study were divided into two groups; 80.67% of the QFT positive subjects had positive TST results, indicating good correlation between QFT-GIT and TST results.
In the majority of other studies, greater diff erence between QFT-GIT and TST results has been documented 2, 5, [15] [16] [17] . Such a diff erence, which favors QFT-GIT test performance, appears to be due to the falsepositive TST results because of previous BCG immunization and due to false-negative TST results in immunocompromised patients 2, 5, [15] [16] [17] . In this study, the prevalence of the history of tuberculosis contact was signifi cantly higher in the study group as compared with the control group (30%:10%). In the control, QFT negative group, only 15 subjects had tuberculosis contact. When TST was performed, only two subjects had moderate reaction, whereas 13 subjects had no reaction. Positive TST results in these two QFT negative patients who had a history of tuberculosis contact and in another two subjects with no history of tuberculosis contact but having TST positive and QFT-GIT negative results can be interpreted as a false-positive TST result, which can occur due to previous BCG immunization and cross-reactivity with non tuberculosis mycobacteria, but not to the extent reported from other studies where this diff erence was much greater 2,5,6,15-17 . Hsia et al. 5 documented that positive TST result was 3-fold higher in BCG-vaccinated than in unvaccinated patients, while the proportion of patients with positive QFT-GIT test results was only 1.5-fold higher in BCG-vaccinated compared with unvaccinated patients. In this study, all patients were BCG-vaccinated. It is important to mention that one-fi fth of QFT positive patients in this group were TST negative. In this study, greater sensitivity of QFT-GIT test as compared to TST, although not statistically signifi cant, was consistent with other so far documented studies, especially when it comes to immunocompromised patients 1, 2, 5 . Some of these studies have reported similar QFT-GIT test results between immunocompromised and healthy subjects, whereas positive TST results were signifi cantly lower in immunocompromised patients when compared with healthy subjects 5, 10 . Although a large proportion of patients in our study were receiving methotrexate and other DMARDs, at the beginning of the study lower corticosteroid doses were used (10 mg/day) and none of the patients received TNF-α antagonist therapy, so generally speaking, no patient had severe comorbid infection. Such immunosuppression did not appear to have a substantial eff ect on TST and QFT-GIT test results. After six weeks of tuberculosis prophylaxis schemes used in this study (6 months of isoniazid), TNF-α antagonist therapy was introduced in QFT positive respondents. Among TNF-α antagonists, adalimumab was most frequently prescribed (48% of subjects), followed by etanercept (30% of subjects).
On second clinical evaluation conducted six months after the fi rst visit and during third clinical evaluation after one-year period, all physical examinations, chest radiographs and microbiological analysis for Mycobacterium tuberculosis (sputum culture 2 times) revealed normal fi ndings in all patients included in the study. After one-year period, QFT-GIT test was performed again in all patients. Conversion to negative result was recorded in 4% of QFT positive subjects, while all QFT negative patients remained negative.
In the United Kingdom (UK), a risk-based strategy such as the BTS UK pre-anti-TNF-α guideline is recommended 18 . Th is emphasizes clinical assessment, and balances the annual risk of developing active tuberculosis (using country of birth and age) against the chance of hepatotoxicity during treatment for LTBI. Th is guideline is in line with the low expected background prevalence of Mycobacterium tuberculosis in UK population, therefore QFT-GIT test results are more likely to be false than genuine true-positive in that kind of population 19 . Although TNF-α antagonist candidates are expected to be at no greater risk of exposure to Mycobacterium tuberculosis than the background population in general, a higher risk of tuberculosis was previously observed among patients with rheumatoid arthritis treated with prednisolone and DMARDs 3 . In this study, rheumatoid arthritis was one of the most frequently present immune diseases with two-times higher incidence in women than in men. Th erefore, performing QFT-GIT test in that kind of population remains fully justifi ed.
Since the BTS guideline was published, the National Institute for Health and Clinical Excellence has issued a guideline discussing non-HIV associated cause of immunosuppression, although not specifi cally mentioning pre-TNF-α antagonist assessment. Th is recommends that screening should include QFT-GIT and/or TST in immunocompromised subjects 20 .
Greveson et al. 1 found QFT-GIT testing to be more favorable than TST in low incidence population where most of the subjects experienced previous BCG immunization, thus avoiding false-positive TST results. Th is is consistent with our results, as all QFT negative but TST positive patients remained negative at the end of the study and, what is most important, did not experience tuberculosis although were administered anti TNF-α therapy without previous prophylaxis.
In our study, older age, history of contact with tuberculosis and smoking signifi cantly infl uenced the QFT-GIT and TST results, pointing to the importance of good clinical examination and detailed medical history, which is in line with the UK pre-TNF-α antagonist guideline 18 . In our analysis, QFT-GIT test showed somewhat greater sensitivity and specifi city when compared with TST, however, without statistical signifi cance, showing that there is no gold standard for LTBI diagnosis and that every case should be analyzed thoroughly. Th is includes complete medical evaluation and detailed medical history. However, unlike TST, QFT-GIT does not require re-visit and its interpretation is less vulnerable to reader error, making this test more favorable. Since the number of patients suff ering from infl ammatory autoimmune diseases in need of TNF-α antagonist is increasing in Croatia, a large cost-eff ectiveness evaluation should be performed. Nevertheless, patients should be informed regarding LTBI assessment, its implications and possible on-going risks.
